An observational study in Atrial Septal Defect and Patent Foramen Ovale, sponsored by atHeart Medical. Status unknown at 1 site in Germany. Per ClinicalTrials.gov, last updated 2022-07-21.
Sponsored by atHeart Medical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Foramen Ovale, Patent with a site in Germany — 3 open to participants now, 6 under way, none of them phase 3. Foramen Ovale, Patent · Germany.
Among the 21 studies in Foramen Ovale, Patent with a site in Germany, this one is one of 3 that started in 2020, is one of 7 observational ones, and was the 15th registered.
137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.
Browse Foramen Ovale, Patent studies →3 of the 21 studies in Foramen Ovale, Patent with a site in Germany are open now. Recruiting first, the newest first:
Giuseppe Tarantini · Sites in Germany
Ages 18–65
Abbott Medical Devices · Sites in Germany, United States, Denmark and 7 more countries
Lifetech Scientific (Shenzhen) Co., Ltd. · Sites in Germany, Korea, Republic of
Ages 18–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2020.
This study's enrollment of 6 is below the median of 252 across 60 observational studies indexed under Foramen Ovale, Patent.
Median enrollment 85 across the 13 interventional studies, 582 across the 7 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 10 most frequent:
atHeart Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.
atHeart Medical has 1 study filed under Foramen Ovale, Patent — fewer than ten, so there is no comparison to draw.
1 of the studies in Foramen Ovale, Patent with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06120270Lifetech Scientific (Shenzhen) Co., Ltd.CeraFlex PFO Closure System PMCF Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Foramen Ovale, Patent with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multi centre, international, post market registry to monitor the clinical performance and safety of an atrial septal closure device with biodegradable framework in patients with clinically significant atrial septum defect (ASD) or patent foramen ovale (PFO) in routine clinical use
137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.
This study's enrollment of 6 is below the median of 252 across 60 observational studies indexed under Foramen Ovale, Patent.
Browse Foramen Ovale, Patent studies →atHeart Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.
Compared within Foramen Ovale, Patent, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Septal Defects, Atrial. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Intent to treat population: All enrolled patients Modified Intent to Treat population: All enrolled patients who have a permanently implanted CBSO.
Per Protocol population: All patients in the enrolled population who have a permanently implanted CBSO and do not have a major protocol deviation. The per protocol population will be used as the final population for analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Septal defect closure
Device: Septal defect closure
Device closure of atrial septal defect
Effective closure by echocardiography
Time frame: at 6 months
Safety throughout the follow up duration by absence of serious incidents
Time frame: day 0 to 3 years
Started Mar 2020 (actual). Primary completion is estimated for Oct 2023, 43 months after the start.
Of 29 observational studies under Foramen Ovale, Patent, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 92. This study's planned 43 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
atHeart Medical